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E-mail address: ipolikarpov@if.sc.usp.br (I. PolikarInterleukin-22 (IL-22) plays an important role in the regulation of immune and inﬂammatory
responses in mammals. The IL-22 binding protein (IL-22BP), a soluble receptor that speciﬁcally binds
IL-22, prevents the IL-22/interleukin-22 receptor 1 (IL-22R1)/interleukin-10 receptor 2 (IL-10R2)
complex assembly and blocks IL-22 biological activity. Here we present the crystal structure of
the IL-22/IL-22BP complex at 2.75 Å resolution. The structure reveals IL-22BP residues critical for
IL-22 binding, which were conﬁrmed by site-directed mutagenesis and functional studies. Compar-
ison of IL-22/IL-22BP and IL-22/IL-22R1 crystal structures shows that both receptors display an over-
lapping IL-22 binding surface, which is consistent with the inhibitory role played by IL-22 binding
protein.
Structured summary:
MINT-7010533: IL-22 BP (uniprotkb:Q969J5) and IL-22 (uniprotkb:Q9GZX6) bind (MI:0407) by X-ray crys-
tallography (MI:0114)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction proteins in human keratinocytes [9] and in lung and gut mucosaeInterleukins (ILs) are cytokines that regulate a variety of physi-
ological and pathological conditions such as normal and malignant
cell growth, as well as immune and inﬂammatory responses, which
makes them obvious targets for clinical applications [1,2]. Some
cytokines have pro-inﬂammatory activities, whereas others pro-
mote healing by reducing inﬂammation. Among these cytokines,
interleukin-22 (IL-22) is involved in the generation of inﬂamma-
tory and immune responses that lead to the development of sev-
eral illnesses such as Crohn’s disease [3], interstitial lung disease
[4], rheumatoid arthritis [5], and psoriasis [6]. On the other hand,
IL-22 has a protective role in liver injury by promoting hepatocyte
survival [7,8]. IL-22 also induces the production of antimicrobialchemical Societies. Published by E
tein; IL-22, interleukin-22; IL-
-10 receptor 2; IL-10, inter-
ember 9; CRF2-4, the second
kine receptor family class 2
2; ORF, open reading frame;
S, ﬂuorescent automatic cell
t mean square deviation; IL-
II domain
pov).from mice [10]. Taken together, these ﬁndings point out that IL-22
is involved in innate pathogen defense, wound healing, and regula-
tion of tissue inﬂammation by mediating the cross talk between
the immune system and epithelial cells [11].
Interleukin-22 is a member of the interleukin 10 (IL-10) super
family of cytokines and it is produced by activated NK and T cells
[12,13]. Nevertheless, a distinct lineage of T helper type 17 cells
(TH17 lineage) expressing IL-22 has recently been identiﬁed [14].
Human IL-22 is a 20 kDa-a-helical protein that signals through
its binding to class II cytokine family cell surface receptors, inter-
leukin-22 receptor 1 (IL-22R1) (cytokine receptor family class 2
member 9, CRF2-9) and interleukin-10 receptor 2 (IL-10R2) (the
second chain of the IL-10 receptor complex, CRF2–4) [15]. While
IL-10R2 is ubiquitously expressed, the IL-22R1 is expressed in a
limited number of normal tissues such as skin, kidney, liver, colon,
small intestine, lung, and pancreas [9,15]. IL-22 ﬁrst associates
with the extracellular domain of IL-22R1 and subsequently with
the extracellular domain of IL-10R2, which binds to a speciﬁc sur-
face created by the interaction between IL-22 and the IL-22R1. This
results in the assembly of a cytokine receptor complex with higher
afﬁnity for IL-22 [16].
Very recently, the three-dimensional structures of the IL-22/IL-
22R1 complex, which were published independently by two differ-
ent groups [17,18], revealed that IL-22 has distinct binding sites forlsevier B.V. All rights reserved.
Table 1
Crystallographic and structural informationa.
Data collection parameters
Space group P41
Cell parameters (Å) a = b = 67.9, c = 172.5
Wavelength (Å) 1.43
Resolution limits (Å) 29.25–2.75 (2.85–2.75)
Completeness (%) 96.52 (98.6)
Redundancy 2.7 (2.5)
Rmerge (%)b 14.5 (50.7)
hI/r(I)i 4.82 (1.6)
Total number of reﬂections 51014 (7389)
Reﬂections used for reﬁnement/Rfree calculations 20447 (995)
Reﬁnement parameters
Rfactor (%)c 21.23
Rfree (%)d 27.93
Bond length mean deviation (Å) 0.010
Bond angles mean deviation () 1.358
Ramachandran plot (%)
Residues in most favored regions 88.8
Residues in additionally allowed regions 11.2
Residues in disallowed regions 0.0
a Values in parentheses refer to the highest resolution shell.
b Rmerge ¼
P
hkl
P
ijIiðhklÞ  hIðhklÞij=
P
hkl
P
iIiðhklÞ, where Ii is the intensity of the
ith observation of reﬂection hkl and hIðhklÞi is the weighted average intensity of
observations i of reﬂections hkl.
c Rfactor ¼
P kFoj  kjFck=
P jFo j, where Fo and Fc are the observed and calculated
structure factor amplitudes.
d Rfree is the same as Rfactor but only for 5% of the data randomly omitted from
reﬁnement.
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loops interact with IL-22 residues within helices A and F, and loop
AB, the IL-10R2 binding site is formed by IL-22 hot spot residues lo-
cated on helices A and D, as described previously [19]. Furthermore,
site-directed mutagenesis and functional studies showed that IL-
22R1 residues Lys58 and Tyr60 are crucial for IL-22 binding [17].
In addition to its cellular receptor, IL-22 binds to a 25 kDa-se-
creted protein termed interleukin-22 binding protein (IL-22BP)
(cytokine receptor family class 2 member 10 (CFR2-10) or IL-22
receptor subunit alpha-2 (IL-22Ra2)), which is highly expressed
in breast, placenta, skin, lungs, spleen, and colon [20–22]. IL-
22BP is a soluble receptor that lacks both trans-membrane and
intracellular domains, and it is highly related to the extracellular
domains of class II cytokine receptors IL-22R1 and IL-20Ra.
Cross-linking experiments showed that IL-22BP speciﬁcally binds
IL-22 with high afﬁnity. Thus, IL-22BP prevents the interaction of
IL-22 with the functional cell surface receptor complex and acts
as a natural IL-22 antagonist [20–22]. This antagonism may be
important for the regulation of inﬂammatory responses induced
by IL-22.
Here we describe the crystal structure of the IL-22/IL-22BP
complex at 2.75 Å resolution, which reveals the molecular basis
of IL-22 recognition by its decoy receptor. The importance of key
amino acid residues identiﬁed by the structure was conﬁrmed by
site-directed mutagenesis of IL-22BP and functional studies. The
IL-22/IL-22BP three-dimensional structure reveals for the ﬁrst time
the molecular mode of IL-22BP antagonism of IL-22 action.
2. Materials and methods
2.1. Complex crystallization, structure determination, and reﬁnement
A single crystal of the IL-22/IL-22BP complex was obtained from
a solution consisting of 10% PEG 6000 and 5%MPD [23]. A complete
data set was collected at theW01B-MX2 beam line at the Laborató-
rio Nacional de Luz Síncrotron (Campinas, São Paulo, Brazil) [24].
The IL-22/IL-22BP structure was solved by molecular replacement
using the coordinates of the IL-22/IL-22R1 complex (PBD 3DLQ).
The model was reﬁned alternating cycles of model manipulation
in COOT [25] and reﬁnement in PHENIX [26]. Stereochemical anal-
ysis was performed with PROCHECK [27]. The statistics for data
processing and model reﬁnement are given in Table 1. Buried sur-
face area was calculated using PISA [28] and PROTORP [29] servers.
Figures and the root mean square deviation (r.m.s.d.) calculations
were done using PyMOL [30]. The atomic coordinates and structure
factors of IL-22/IL-22BP complex have been deposited in the Pro-
tein Data Bank under accession code 3G9V.2.2. Cellular assays for IL-22BP and IL-22R1
To allow for its cell surface expression, the mIL-22BP open read-
ing frame (ORF) cDNA was ampliﬁed by PCR and cloned into the
pDisplay vector (Invitrogen) containing the sequence coding for
the platelet-derived growth factor receptor (PDGF-R) trans-mem-
brane domain. Mutagenesis on hIL-22R1 and mIL-22BP was per-
formed by using the GeneEditor in vitro Site-Directed
Mutagenesis System (Promega). Clones obtained were sequenced
using the DYEnamic ET Dye Terminator Kit (Amersham Biosci-
ences). For stable transfections, 5  106 BW5147 cells were elec-
troporated (270 V, 74X, 1500 lF) with 50 lg of sterile DNA in
800 ll complete medium, and selected using puromycine (1.6 lg/
mL; Sigma). Cells expressing the receptor constructs were sorted
by ﬂuorescent automatic cell sorter (FACS) analysis with a mouse
monoclonal anti-hIL-22R antibody (MH22R6.6) or a biotinylated
mouse monoclonal anti-IL-22BP (AM22BP.4), followed by ﬂuores-cein isothiocyanate (FITC)-conjugated goat anti-mouse antibody
(Becton-Dickinson) or phycoerythrin-conjugated streptavidin
(Becton-Dickinson), respectively. Proliferation assays were per-
formed as described previously [17].
3. Results and discussion
3.1. Quality of the model
We determined the crystal structure of the IL-22/IL-22BP com-
plex at 2.75 Å resolution (Table 1). There are two IL-22/IL-22BP
complexes (B/A and D/C) in the crystallographic asymmetric unit
related by a non-crystallographic twofold axis. These heterodimers
are essentially identical (0.098 Å r.m.s.d. for 285 Ca atoms), and
thereafter the coordinates of the B/A complex will be considered
for structural and comparison analyses. The ﬁnal model includes
IL-22BP residues 29–225 and 26–223 (for chains A and C, respec-
tively), IL-22 residues 38–178 and 41–179 (for chains B and D,
respectively), and 221 water molecules. Several polypeptide frag-
ments of IL-22BP (chains A and C, residues 53–55, 137–141,
177–182, 196–205) and IL-22 (chain B, residues 134–139; chain
D, residues 131–139) were not included in the ﬁnal model because
of poor or disordered electron density. The Ramachandran plot
indicated that a total of 88.8% and 11.2% of the 835 amino acid res-
idues were in the most favorable and additionally allowed regions,
respectively, and no residues were found in the disallowed regions.3.2. Overall IL-22/IL-22BP complex architecture
In the IL-22/IL-22BP complex, the IL-22 molecule folds in a com-
pact bundle of six anti-parallel a-helices, whereas the IL-22BP mol-
ecule folds in an L-shaped structure consisting of two ﬁbronectin-
III domains (FBN-III) in tandem (Fig. 1A). Each FBN-III domain con-
sists of a sandwich of two anti-parallel b-sheets formed from seven
b-strands (A, B, E and C, C0, F, and G). The N-terminal D1 domain
(residues 29–121) is connected to the C-terminal D2 domain (res-
idues 126–225) by a small 310 a-helix (residues 122–125). IL-22BP
Fig. 1. Crystallographic structure of human IL-22/IL-22BP complex. (A) Ribbon representation of the IL-22/IL-22BP complex, showing the binding interfaces (site 1a and site
1b) outlined by boxes. IL-22BP is purple blue, IL-22 is cyan, and disulﬁde bridges of IL-22BP and IL-22 are cyan and yellow, respectively. (B) Stereo view of the IL-22/IL-22BP
site 1a showing the electrostatic contacts between the side chains of IL-22BP (purple blue) and IL-22 (cyan) residues. (C) Stereo view of the IL-22/IL-22BP site 1b showing the
hydrophobic cluster of IL-22BP (purple blue) and IL-22 (cyan). Water molecules are yellow spheres, and intermolecular hydrogen bonds are shown as dashed black lines.
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similar to that described for the extracellular portion of the IL-
22R1 chain (121) [17], and 10 larger than that observed in the
interleukin-10 receptor 1 (IL-10R1) chain (115) [31].
There are two disulﬁde bridges in the IL-22BP structure: the
ﬁrst between Cys78 and Cys86, that connects strands C0 with E
(in the D1 domain), and the second that links b-strand F
(Cys206) to b-strand G (Cys227) in the D2 domain (Supplementary
Fig. S1). The ﬁrst disulﬁde bridge is structurally equivalent to
Cys71/Cys79 (IL-22R1) and Cys66/Cys74 (IL-10R2), but it is not
equivalent to Cys56/Cys75 (IL-10R1) that connects b-strands C0
with C. The second disulﬁde bridge of IL-22BP is conserved in IL-
10R1, IL-10R2, and all other class II cytokine receptors, but it is
not equivalent to the disulﬁde bridge of IL-22R1 that links b-strand
A (Cys128) to b-strand G (Cys217). Thus, there is a difference in the
Cys/Cys connectivity of the C-terminal D2 domains of IL-22BP and
IL-22R1.
Sequence alignments show that human IL-22BP has 34%, 29%,
and 30% amino acid identity with the extracellular domains of IL-
22R1, IL-10R1, and IL-10R2, respectively (Supplementary Fig. S1).
Although IL-22BP and IL-22R1 share limited amino acid sequence
identity, the three-dimensional structure of IL-22BP is topologi-
cally very similar to the extracellular portion of IL-22R1 (1.68 Å
r.m.s.d., 119 Ca atoms). IL-22BP D1 (residues 29–121) domain is
structurally most similar to D1 (residues 20–113) of IL-22R1
(0.81 Å r.m.s.d, 76 Ca atoms). On the other hand, IL-22BP D2 (res-
idues 126–225) domain exhibits considerable primary structure
differences with D2 (residues 119–228) of IL-22R1 (21% amino acid
identity), which leads to a signiﬁcant dissimilarity in their 3D
structures (3.57 Å r.m.s.d., 51 Ca atoms).
3.3. Molecular details of the IL-22/IL-22BP binding interface
IL-22BP contacts IL-22 using ﬁve binding loops (L2–L6) (Fig. 1A),
as observed for the IL-22/IL-22R1 and IL-10/IL-10R1 complexes
[17,18,31]. At the D1 domain (site 1a), IL-22BP residues within
loops L2–L4 form 16 hydrogen bond/salt bridge interactions withIL-22 residues located in the loop AB (Asp67, Thr70, Asp71,
Val72, Arg73, Glu77) and on the bend in helix F1 (Lys162,
Gly165, Glu166) (Fig. 1B). The IL-22BP residue Tyr67 dominates
the molecular recognition of IL-22 by IL-22BP. Tyr67 makes ﬁve di-
rect contacts and one water-mediated interaction with IL-22 resi-
dues, including Lys162 and Glu166 that are part of the IL-10
signature (162KAIGELDLL). In addition, three IL-22BP residues
(Lys65, Glu97, and Arg119) form ﬁve salt bridge interactions with
IL-22 residues located on the AB loop (Supplementary Table S1).
There are fewer electrostatic interactions at the D2 domain (site
1b) (Fig. 1C). IL-22BP loops L5 and L6 contact IL-22 residues located
on the beginning of helices pre-A (Phe47) and A (Thr53, Asn54,
Phe57), and the C-terminus of helix F2 (Phe171, Met172,
Arg175). The two large aromatic residues Trp123 and Trp124 of
IL-22BP interact with the hydrophobic patch formed by hydropho-
bic residues (Phe47, Phe57, Phe171, and Met172) of IL-22 and IL-
22BP residues Met215 and Leu216. In addition to hydrophobic
interactions, IL-22BP residues Glu168, Met215, and Leu216 are in-
volved in some hydrogen bond/salt bridge contacts across the site
1b interface (Supplementary Table S1).
Very recently, Jones and co-workers, used homology modeling
of the IL-22/IL-22BP complex to propose ﬁve putative interactions
at the IL-22/IL-22BP interface: Lys44/Glu168, Gln48/Met215,
Asn54/Asp217, Lys61/Glu125, and Arg175/Glu168 [18]. Our IL-
22/IL-22BP crystal structure reveals that only one of them, the salt
bridge interaction Arg175/Glu168, exists across the binding inter-
face. The other four potential hydrogen bonds do not occur as
the distances between the side chains of the correspondent resi-
dues are all greater than 5 Å.
3.4. Structural comparison of IL-22/IL-22BP and IL-22/IL-22R1 binding
interfaces
The IL-22/IL-22BP complex structure is similar to IL-22/IL-22R1
(2.70 Å r.m.s.d., 259 Ca atoms; PDB 3DLQ) and IL-22/sIL-22R1
(2.86 Å r.m.s.d., 263 Ca atoms; PDB 3DGC) crystal structures
(Fig. 2A). Upon IL-22/IL-22BP complex formation, 26 IL-22 residues
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ilarly, 51 residues of the IL-22/IL-22R1 interface bury 1710 Å2 of
surface area [17]. However, 23 electrostatic contacts are formed
between IL-22 and IL-22BP, whereas only 16 hydrogen bond/salt
bridge interactions are found in the IL-22/IL-22R1 binding interface
(Fig. 2B and C).
In both IL-22/IL-22BP and IL-22/IL-22R1 complexes, site 1a ac-
counts for the majority of the total buried surface area between
IL-22 and IL-22BP (1127 Å2) or IL-22R1 (996 Å2). Moreover, site
1a contains 10 conserved hydrogen bond/salt bridge interactions
(Supplementary Table S2). These electrostatic contacts are formed
between eight IL-22 residues and IL-22BP residues Lys65, Tyr67,
Gly68, Glu97, and Arg119, which are structurally equivalent to
IL-22R1 residues Lys58, Tyr60, Gly61, Glu90, and Arg112, respec-
tively (Fig. 2B). Three of the six salt bridges found in the IL-22/IL-
22BP site 1a (Asp67/Arg119, Asp71/Lys65, Arg73/Glu97) are con-
served in the IL-22/IL-22R1 complex (Asp67/Arg112, Asp71/
Lys58, Arg73/Glu90). These conserved interactions are important
in the stabilization of both complex structures.Fig. 2. Comparison of IL-22/IL-22BP and IL-22/IL-22R1 binding interfaces. (A) Superposit
crystal structures shows their binding interfaces outlined by boxes. The IL-22BP interdo
respectively. (B and C) Site 1a (B) and site 1b (C) of superimposed IL-22/IL-22BP and IL-22
in (A). Key interacting residues are shown as sticks that are labeled red (IL-22R1) or black
and green (of IL-22/IL-22R1) spheres, and hydrogen bonds are shown as dashed black line
(E) binding interfaces with positive (blue) and negative (red) electrostatic potentials. E
potentials were mapped onto the molecular surface and contoured at ±35 kT/eV (blue/rIn addition to the electrostatic interactions, both complexes
contain a hydrophobic cluster located at site 1b, which buries
776 Å2 and 720 Å2 of IL-22/IL-22BP and IL-22/IL-22R1 interface
areas, respectively (Fig. 2C). Superposition of binary complexes re-
veals that IL-22/IL-22R1 site 1b contains a smaller hydrophobic
cluster and fewer solvent-exposed non-polar residues than IL-22/
IL-22BP site 1b. Interestingly, there is a unique salt bridge interac-
tion formed between IL-22BP residue Glu168 and IL-22 helix F2
residue Arg175. This salt bridge does not exist in the IL-22/IL-
22R1 site 1b interface because the side chain of Arg175 adopts a
different conformation to interact with Thr207 from IL-22R1. Addi-
tionally, one conserved water molecule mediates the interaction
between IL-22 residues Phe47 and Thr53 with residues Met216
(of IL-22BP) and Pro216 (of IL-22R1).
Very recently, a detailed mutagenesis study has identiﬁed four
and 12 IL-22 residues that are important for IL-22BP and IL-22R1
binding, respectively [32]. Among these IL-22 residues, Asp67,
Arg73, and Lys162 side chains are critical for optimal binding to
IL-22BP and IL-22R1, which is consistent with the result from theion of IL-22/IL-22BP (cyan/purple blue) and IL-22/IL-22R1 (yellow/red) (PDB 3DLQ)
main angle is shown. Disulﬁde bridges of IL-22BP and IL-22R1 are cyan and yellow,
/IL-22R1 structures are depicted in stereo. The color designation is the same as that
(IL-22BP and both IL-22 molecules). Water molecules are yellow (of IL-22/IL-22BP)
s. (D and E) Surface potential representation of IL-22/IL-22BP (D) and IL-22/IL-22R1
ach panel represents an ‘‘open book” view of the complex interface. Electrostatic
ed), and calculated using PyMOL APBS tools [33].
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lographic models (Fig. 2A–C).
3.5. The molecular recognition of IL-22 by IL-22BP and IL-22R1
receptors
Analysis of the IL-22/IL-22BP and IL-22/IL-22R1 binding inter-
faces showed that IL-22BP and IL-22R1 bind to similar surfaces
on IL-22 (Fig. 2A–C). Comparison of surface electrostatic potential
at the IL-22/IL-22BP and IL-22/IL-22R1 interfaces reveals good
charge complementarity at site 1a (Fig. 2D and E). Nevertheless,
there are lower electrostatic and hydrophobic complementarities
between IL-22 and IL-22R1 at the site 1b interface. An interesting
feature of the IL-22 binding interface is the presence of a shallow
cavity formed by residues within helix F1 (Lys162, Gly165,
Glu166) and loop AB (Asp67), where the hydroxyl group of Tyr67
residue from IL-22BP is inserted (Fig. 2D). IL-22BP Tyr67 is struc-
turally equivalent to IL-22R1 Tyr60, and the latter ﬁts into the
same cavity formed by the intersection between IL-22 helix F1
and loop AB (Fig. 2E). However, IL-22BP Tyr67 makes more direct
electrostatic interactions with IL-22 residues than Tyr60 of IL-
22R1 [17].
The binding of IL-22 to IL-22BP is of extremely high afﬁnity
(Kd  1 pM), in comparison with the high binding afﬁnity between
IL-22 and the extracellular domain of IL-22R1 (Kd  20 nM) [18].
Our X-ray structure of the IL-22/IL-22BP complex and its compar-
ison with IL-22/IL-22R1 reveal a number of structural differences
in the recognition of IL-22 by IL-22BP and IL-22R1 that shed light
on the differences in their binding afﬁnities. First, the number of
electrostatic interactions found at the IL-22/IL-22BP interface is
higher, as evidenced by the higher degree of charge complementar-
ity compared with the IL-22/IL-22R1 interface. Second, eight of 10
conserved electrostatic interactions are shorter in the IL-22/IL-
22BP site 1a interface, indicating that IL-22BP binds to IL-22 more
tightly. Third, IL-22BP makes more direct protein–protein interac-
tions, whereas IL-22R1 shows direct and water-mediated interac-
tions with IL-22. Finally, the IL-22/IL-22BP complex contains a
larger hydrophobic cluster centered at site 1b that contributes to
strengthen the interaction between IL-22 and IL-22BP. Thus, the
combined effects of electrostatic and hydrophobic contacts acrossFig. 3. The inﬂuence of mIL-22BP mutants in the mIL-22 binding. (A and B) Fluorescence-
cell surface expression and mIL-22 binding activities. Left panels, 105 BWIL-22BP cells fro
22BP monoclonal antibody (0.5 lg/mL) followed by phycoerythrin-conjugated streptavid
of biotinylated mIL-22 (6.8 ng/mL). The binding was detected with phycoerythrin-conjug
or mutant R112A) cells were stimulated in triplicates with various dilutions of hIL-22 for
results correspond to the mean and SD from triplicate cultures.the IL-22/IL-22BP binding interface contribute to the high binding
afﬁnity of the complex.
3.6. Determination of the IL-22BP functional epitopes by site-directed
mutagenesis
To assess the functional importance of the IL-22BP residues for
IL-22 binding, we mutated key amino acid residues located at the
complex interface using site-directed mutagenesis. Two IL-22BP
residues were chosen (Tyr67 and Arg119), due to their participa-
tion in several hydrogen bond/salt bridge interactions with the
IL-22 molecule (Fig. 1B; Supplementary Table S1). These selected
residues are structurally equivalent to Tyr66 and Arg118 residues
from murine IL-22BP (mIL-22BP). Thus, two murine mutants were
generated (Y66A and R118A) in order to test their abilities to bind
to murine IL-22 (mIL-22) in a cell-based assay. These mutations
were inserted into a cell surface version of mIL-22BP obtained by
cloning the IL-22BP ORF in frame with the PDGF-R trans-mem-
brane domain. Wild type mIL-22BP was used as an internal control.
While human and murine IL-22 share 79% amino acid identity, hu-
man IL-22BP has 67% sequence identity with its murine ortholog
(Supplementary Figs. S2 and S3). According to the amino acid se-
quence alignments, murine residues Tyr66 and Arg118 are all con-
served in human IL-22BP (hIL-22BP) and IL-22R1 (hIL-22R1).
At the IL-22/IL-22BP interface, hIL-22BP Tyr67 side chain forms
an extensive hydrogen bond network with Asp67, Val72, Lys162,
and Glu166 residues of IL-22. These interactions have their coun-
terparts in the IL-22/IL-22R1 complex, where IL-22R1 Tyr60 makes
direct and water-mediated interactions with the same IL-22 resi-
dues (Fig. 2B). In order to check the importance of Tyr67 for IL-
22/IL-22BP binding, the structurally equivalent murine residue
Tyr66 was mutated to an Ala residue. The mIL-22BP Y66A muta-
tion completely abolished mIL-22 binding (Fig. 3A). The same re-
sult was obtained for IL-22R1 mutants Y60R and Y60A that
completely failed to respond to IL-22 [17], indicating that a tyro-
sine residue at this position in IL-22R1 and IL-22BP is critical for
IL-22 binding.
Another important salt bridge found at the IL-22 molecular
interface involves IL-22 residue Asp67 and hIL-22BP residue
Arg119, which is structurally equivalent to Arg112 of IL-22R1activated cell sorting (FACS) analysis of mIL-22BP (WT or mutants Y66A and R118A)
m two independent experiments were analyzed by FACS with a biotinylated anti-IL-
in labeling. Right panels, 105 BWIL-22BP cells were analyzed by FACS for the binding
ated streptavidin. (C) Inhibition of BWhIL-22R1 cell proliferation. BWhIL-22R1 (WT
72 h and proliferation was assessed by measuring H3-thymidine incorporation. The
P.R. de Moura et al. / FEBS Letters 583 (2009) 1072–1077 1077(Fig. 2B). In order to assess the functional role of Arg119 residue for
IL-22/IL-22BP binding, the structurally equivalent murine residue
Arg118 was mutated to an Ala residue. The murine R118A point
mutant affected partially the mIL-22BP expression, but it com-
pletely abolished mIL-22 binding (Fig. 3B). When Arg112 was mu-
tated to an Ala residue, the IL-22R1 R112A mutant completely
abolished the IL-22 response, reﬂecting its importance in IL-22/
IL-22R1 binding (Fig. 3C).
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